Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial
Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin?
Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.